Aprea Therapeutics Inc APRE:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/10/24 EDT
5.22UNCH (UNCH)
Volume
11,128
52 week range
2.78 - 8.85
Loading...
  • Open5.48
  • Day High5.66
  • Day Low5.16
  • Prev Close5.50
  • 52 Week High8.85
  • 52 Week High Date03/01/24
  • 52 Week Low2.78
  • 52 Week Low Date07/07/23

Key Stats

  • Market Cap28.346M
  • Shares Out5.43M
  • 10 Day Average Volume0.01M
  • Dividend-
  • Dividend Yield-
  • Beta1.09
  • YTD % Change18.94

KEY STATS

  • Open5.48
  • Day High5.66
  • Day Low5.16
  • Prev Close5.50
  • 52 Week High8.85
  • 52 Week High Date03/01/24
  • 52 Week Low2.78
  • 52 Week Low Date07/07/23
  • Market Cap28.346M
  • Shares Out5.43M
  • 10 Day Average Volume0.01M
  • Dividend-
  • Dividend Yield-
  • Beta1.09
  • YTD % Change18.94

RATIOS/PROFITABILITY

  • EPS (TTM)-3.99
  • P/E (TTM)-1.31
  • Fwd P/E (NTM)-1.77
  • EBITDA (TTM)-15.465M
  • ROE (TTM)-67.08%
  • Revenue (TTM)583,239.973
  • Gross Margin (TTM)-
  • Net Margin (TTM)-2,449.55%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/13/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Aprea Therapeutics Inc

 

Profile

MORE
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company's advanced synthetic lethality product candidate is ATRN-119, a clinical-stage small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR) a kinase that plays a critical role in DNA damage response (DDR). ATR and Checkpoint Kinase 1 are critical DDR kinases that prevent the collapse of replication forks into DNA...
Richard Peters M.D., Ph.D.
Independent Chairman of the Board
Oren Gilad Ph.D.
President, Chief Executive Officer, Director
John Hamill
Chief Financial Officer, Senior Vice President, Secretary
Address
3805 OLD EASTON ROAD
Doylestown, PA
18902
United States

Top Peers

SYMBOLLASTCHG%CHG
FEMY
Femasys Inc
1.21UNCHUNCH
RNXT
RenovoRx Inc
1.45UNCHUNCH
CNTX
Context Therapeutics Inc
1.87UNCHUNCH
ENLV
Enlivex Therapeutics Ltd
1.50UNCHUNCH
UBX
UNITY Biotechnology Inc
1.53UNCHUNCH